A detailed history of Group One Trading, L.P. transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Group One Trading, L.P. holds 41,594 shares of CRDF stock, worth $105,648. This represents 0.0% of its overall portfolio holdings.

Number of Shares
41,594
Previous 34,776 19.61%
Holding current value
$105,648
Previous $77,000 44.16%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.05 - $2.77 $13,976 - $18,885
6,818 Added 19.61%
41,594 $111,000
Q2 2024

Aug 14, 2024

BUY
$2.22 - $5.89 $54,705 - $145,141
24,642 Added 243.16%
34,776 $77,000
Q1 2024

May 10, 2024

SELL
$1.46 - $5.91 $3,274 - $13,256
-2,243 Reduced 18.12%
10,134 $54,000
Q4 2023

Feb 14, 2024

SELL
$0.96 - $1.55 $20,953 - $33,831
-21,827 Reduced 63.81%
12,377 $18,000
Q3 2023

Nov 09, 2023

BUY
$1.38 - $2.18 $8,594 - $13,577
6,228 Added 22.26%
34,204 $47,000
Q2 2023

Aug 09, 2023

BUY
$1.37 - $1.95 $8,003 - $11,391
5,842 Added 26.39%
27,976 $41,000
Q1 2023

May 12, 2023

BUY
$1.45 - $2.09 $32,094 - $46,260
22,134 New
22,134 $36,000
Q3 2022

Nov 09, 2022

SELL
$1.54 - $3.21 $49,049 - $102,238
-31,850 Reduced 87.33%
4,619 $7,000
Q2 2022

Aug 11, 2022

SELL
$1.17 - $2.61 $8,289 - $18,491
-7,085 Reduced 16.27%
36,469 $80,000
Q1 2022

May 12, 2022

BUY
$2.11 - $7.25 $10,345 - $35,546
4,903 Added 12.69%
43,554 $108,000
Q4 2021

Feb 11, 2022

SELL
$5.18 - $7.24 $174,400 - $243,756
-33,668 Reduced 46.55%
38,651 $232,000
Q3 2021

Nov 12, 2021

BUY
$5.01 - $7.58 $314,106 - $475,235
62,696 Added 651.52%
72,319 $482,000
Q2 2021

Aug 10, 2021

BUY
$6.65 - $10.04 $63,992 - $96,614
9,623 New
9,623 $64,000

Others Institutions Holding CRDF

About Cardiff Oncology, Inc.


  • Ticker CRDF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,334,900
  • Market Cap $110M
  • Description
  • Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...
More about CRDF
Track This Portfolio

Track Group One Trading, L.P. Portfolio

Follow Group One Trading, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Group One Trading, L.P. with notifications on news.